Progress in the study of BLyS and APRIL on regulating T cell responses in rheumatoid arthritis.
- Author:
Yan CHANG
1
;
Wei WEI
Author Information
1. Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei 230032, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies, Monoclonal, Humanized;
therapeutic use;
Arthritis, Rheumatoid;
drug therapy;
metabolism;
pathology;
B-Cell Activating Factor;
metabolism;
B-Cell Activation Factor Receptor;
metabolism;
B-Cell Maturation Antigen;
metabolism;
B-Lymphocytes;
metabolism;
pathology;
Humans;
Lymphocyte Activation;
Recombinant Fusion Proteins;
therapeutic use;
T-Lymphocytes;
metabolism;
pathology;
Transmembrane Activator and CAML Interactor Protein;
metabolism;
Tumor Necrosis Factor Ligand Superfamily Member 13;
metabolism
- From:
Acta Pharmaceutica Sinica
2013;48(7):979-985
- CountryChina
- Language:Chinese
-
Abstract:
B lymphocyte stimulator (BLyS), a tumor neurosis factor ligand superfamily, is an important factor of B cell survival and activation. However, BLyS also regulates T cell activation and survival, playing key roles in T cell-mediated autoimmune disorders. In the paper, we introduced the mechanisms of BLyS and a proliferation-inducing ligand (APRIL) regulating T cell responses and their roles in rheumatoid arthritis (RA).
